Switched memory B‐cells and increased BCR diversity are also significantly enriched in tumours from patients who responded to ICB (Helmink et al., 2020), and some therapies enhance plasma cell TLS differentiation (Soiffer et al., 1998). Here, BCR is linked to neoplasm.